These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23463698)

  • 1. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies.
    Bisaglia M; Greggio E; Beltramini M; Bubacco L
    FASEB J; 2013 Jun; 27(6):2101-10. PubMed ID: 23463698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?
    Bisaglia M; Filograna R; Beltramini M; Bubacco L
    Ageing Res Rev; 2014 Jan; 13():107-14. PubMed ID: 24389159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Free radicals and ailing proteins--the culprits behind Parkinson disease?].
    Smith R; Lotharius J; Brundin P
    Lakartidningen; 2003 Apr; 100(15):1324-6, 1329-30. PubMed ID: 12739402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
    Matsubara E; Shoji M; Abe K
    Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current therapeutic approach in Parkinson disease].
    Przedborski S; Levivier M
    Rev Med Brux; 1992 Dec; 13(10):360-6. PubMed ID: 1480887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon.
    Sawada H; Shimohama S; Tamura Y; Kawamura T; Akaike A; Kimura J
    J Neurosci Res; 1996 Jan; 43(1):55-62. PubMed ID: 8838574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanisms and treatments of Parkinson disease].
    Pollak P
    Rev Prat; 1997 May; 47(10):1068-76. PubMed ID: 9208669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Problems and future perspectives in the treatment of Parkinson's disease].
    Hens L; Hellemans J
    Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic targets for Parkinson's disease.
    Stoessl J
    Expert Opin Ther Targets; 2008 Apr; 12(4):425-36. PubMed ID: 18348679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
    Ekstrand MI; Galter D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease.
    Bayersdorfer F; Voigt A; Schneuwly S; Botella JA
    Neurobiol Dis; 2010 Oct; 40(1):113-9. PubMed ID: 20211259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.
    Bellucci A; Navarria L; Zaltieri M; Missale C; Spano P
    Brain Res; 2012 Jan; 1432():95-113. PubMed ID: 22153624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The recent advance of treatment of Parkinson's disease].
    Matsubara E
    Nihon Rinsho; 2004 Sep; 62(9):1725-8. PubMed ID: 15462392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanism of specific dopaminergic neuronal death in Parkinson's disease].
    Ogawa N; Asanuma M; Miyoshi K
    Nihon Rinsho; 2004 Sep; 62(9):1629-34. PubMed ID: 15462376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptor agonists in the treatment of advanced Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.